Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:FTCYOTCMKTS:IMUNNASDAQ:OBSVNASDAQ:ORGS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTCYGlobal Future City$0.00$0.05▼$1.00$2.04M-0.614,221 shs16 shsIMUNImmune Therapeutics$0.09$0.09$0.07▼$1.30$7.78M0.4615,246 shs12 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs1,640 shsORGSOrgenesis$1.33-13.1%$1.94$0.87▼$10.80$7.34M0.478,399 shs12,038 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFTCYGlobal Future City0.00%0.00%0.00%0.00%0.00%IMUNImmune Therapeutics0.00%0.00%0.00%0.00%0.00%OBSVObsEva0.00%0.00%0.00%0.00%0.00%ORGSOrgenesis-13.07%-20.36%-31.76%-47.22%+132,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFTCYGlobal Future CityN/AN/AN/AN/AN/AN/AN/AN/AIMUNImmune TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/AORGSOrgenesis1.8866 of 5 stars0.05.00.04.40.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFTCYGlobal Future City 0.00N/AN/AN/AIMUNImmune Therapeutics 0.00N/AN/AN/AOBSVObsEva 0.00N/AN/AN/AORGSOrgenesis 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFTCYGlobal Future CityN/AN/AN/AN/AN/AN/AIMUNImmune TherapeuticsN/AN/AN/AN/A($0.03) per shareN/AOBSVObsEvaN/AN/AN/AN/A$0.41 per shareN/AORGSOrgenesis$662K9.64N/AN/A($6.58) per share-0.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFTCYGlobal Future CityN/AN/A0.00N/AN/AN/AN/AN/AN/AIMUNImmune Therapeutics-$3.54MN/A0.00∞N/AN/AN/A-544.75%N/AOBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/AORGSOrgenesis-$55.36MN/A0.00∞N/A-3,827.81%N/A-130.18%8/6/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFTCYGlobal Future CityN/AN/AN/AN/AN/AIMUNImmune TherapeuticsN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/AORGSOrgenesisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFTCYGlobal Future CityN/AN/AN/AIMUNImmune TherapeuticsN/AN/AN/AOBSVObsEvaN/A0.610.61ORGSOrgenesisN/A0.070.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFTCYGlobal Future CityN/AIMUNImmune TherapeuticsN/AOBSVObsEva17.52%ORGSOrgenesis22.56%Insider OwnershipCompanyInsider OwnershipFTCYGlobal Future CityN/AIMUNImmune Therapeutics50.59%OBSVObsEva14.40%ORGSOrgenesis5.66%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFTCYGlobal Future CityN/A40.66 millionN/ANot OptionableIMUNImmune Therapeutics283.66 million41.34 millionNot OptionableOBSVObsEva5077.97 million66.74 millionNot OptionableORGSOrgenesis1504.80 million4.53 millionNo DataFTCY, OBSV, IMUN, and ORGS HeadlinesRecent News About These CompaniesOrgenesis Delays Filing of Quarterly ReportMay 16, 2025 | tipranks.comOrgenesis Delays 10-K Filing Amid Financial ChallengesApril 1, 2025 | tipranks.comOrgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury TherapiesMarch 6, 2025 | accessnewswire.comAOrgenesis Inc. (ORGS) Stock Price, News, Quote & History - Yahoo FinanceFebruary 9, 2025 | finance.yahoo.comOrgenesis secures $5M equity investment from Williamsburg VentureJanuary 29, 2025 | markets.businessinsider.comOrgenesis Inc: Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture HoldingsJanuary 28, 2025 | finanznachrichten.deOrgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture HoldingsJanuary 28, 2025 | accessnewswire.comAOrgenesis Inc. Reports Q3 2024 Financial ResultsNovember 15, 2024 | markets.businessinsider.comOrgenesis Provides Third Quarter 2024 Business UpdateNovember 13, 2024 | markets.businessinsider.comOrgenesis Expands Board with Three New AppointmentsNovember 3, 2024 | markets.businessinsider.comOrgenesis commences trading on OTCQX Best MarketOctober 22, 2024 | markets.businessinsider.comOrgenesis Commences Trading on OTCQX® Best MarketOctober 21, 2024 | markets.businessinsider.comOrgenesis (NASDAQ:ORGS) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.com45O.SG,0P0001J8IU,0 (45O.SG)September 24, 2024 | au.finance.yahoo.comWhy Orgenesis (ORGS) Stock Is Down 23% TodaySeptember 24, 2024 | msn.comOrgenesis Inc.: Orgenesis Announces Reverse Stock SplitSeptember 23, 2024 | finanznachrichten.deOrgenesis Approves 1-for-10 Reverse Stock SplitSeptember 23, 2024 | markets.businessinsider.comOrgenesis Announces Reverse Stock SplitSeptember 23, 2024 | markets.businessinsider.comIs Orgenesis Stock (ORGS) a Good Investment?September 19, 2024 | aaii.comAOrgenesis Advancing CD19 CAR T-cell Therapy Into Phase I/II Leukemia TrialAugust 31, 2024 | precisionmedicineonline.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFTCY, OBSV, IMUN, and ORGS Company DescriptionsGlobal Future City OTCMKTS:FTCYGlobal Future City Holding, Inc. is an holding company. It focused in the areas of consumer product sales and EB-5 investments. The company was founded on October 12, 2000 and is headquartered in Irvine, CA.Immune Therapeutics OTCMKTS:IMUN$0.09 0.00 (0.00%) As of 10/19/2023Immune Therapeutics, Inc. does not have significant operations. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in October 2014. Immune Therapeutics, Inc. is based in Winter Park, Florida.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.Orgenesis NASDAQ:ORGS$1.33 -0.20 (-13.07%) As of 07/3/2025 12:46 PM EasternOrgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
